Current practice and future directions in the prevention and acute management of migraine

被引:167
作者
Goadsby, Peter J. [1 ]
Sprenger, Till [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, Headache Grp, San Francisco, CA 94115 USA
关键词
TOXIN TYPE-A; CHRONIC DAILY HEADACHE; OCCIPITAL NERVE-STIMULATION; PLACEBO-CONTROLLED TRIAL; NEUROTOXIN TYPE-A; CORTICAL SPREADING DEPRESSION; DIHYDROERGOTAMINE NASAL SPRAY; MEDICATION-OVERUSE HEADACHE; 5-HT1F RECEPTOR AGONIST; DOUBLE-BLIND;
D O I
10.1016/S1474-4422(10)70005-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Migraine is a common and disabling brain disorder with a strong inherited component. Because patients with migraine have severe and disabling attacks usually of headache with other symptoms of sensory disturbance (eg, light and sound sensitivity), medical treatment is often required. Patients can be managed by use of acute attack therapies (eg, simple analgesics or non-steroidal anti-inflammatory drugs) or specific agents with vasoconstrictor proper-ties (ie, triptans or ergot derivatives). Future non-vasoconstrictor approaches include calcitonin gene-related peptide receptor antagonists. Preventive therapy is probably indicated in about a third of patients with migraine, and a broad range of pharmaceutical and non-pharmaceutical options exist. Medication overuse is an important concern in migraine therapeutics and needs to be identified and managed. In most patients, migraine can be improved with careful attention to the details of therapy, and in those for whom it cannot, neuromodulation approaches, such as occipital nerve stimulation, are currently being actively studied and offer much promise.
引用
收藏
页码:285 / 298
页数:14
相关论文
共 225 条
[1]   Comparison of rizatriptan and other triptans on stringent measures of efficacy [J].
Adelman, JU ;
Lipton, RB ;
Ferrari, MD ;
Diener, HC ;
McCarroll, KA ;
Vandormael, K ;
Lines, CR .
NEUROLOGY, 2001, 57 (08) :1377-1383
[2]   Greater occipital nerve injection in primary headache syndromes - prolonged effects from a single injection [J].
Afridi, S. K. ;
Shields, K. G. ;
Bhola, R. ;
Goadsby, P. J. .
PAIN, 2006, 122 (1-2) :126-129
[3]  
*AM AC NEUR, AAN GUID SUMM CLIN M
[4]  
Andrasik Frank, 2004, Expert Rev Neurother, V4, P403, DOI 10.1586/14737175.4.3.403
[5]   Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A [J].
Aoki, KR .
NEUROTOXICOLOGY, 2005, 26 (05) :785-793
[6]  
ARTHUR G P, 1971, New Zealand Medical Journal, V73, P5
[7]   Botulinum toxin type A prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study [J].
Aurora, Sheena K. ;
Gawel, Marek ;
Brandes, Jan L. ;
Pokta, Suriani ;
VanDenburgh, Amanda M. .
HEADACHE, 2007, 47 (04) :486-499
[8]   Suppression of cortical spreading depression in migraine prophylaxis [J].
Ayata, C ;
Jin, HW ;
Kudo, C ;
Dalkara, T ;
Moskowitz, MA .
ANNALS OF NEUROLOGY, 2006, 59 (04) :652-661
[9]  
Barrientos N., 2003, J HEADACHE PAIN, V4, P146, DOI [10.1007/s10194-003-0049-2, DOI 10.1007/S10194-003-0049-2]
[10]   Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input [J].
Bartsch, T ;
Goadsby, PJ .
BRAIN, 2002, 125 :1496-1509